Seeking Alpha

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines, announced ...
Hosted on MSN

Oral-B’s new iO10 electric toothbrush is absurdly luxurious – and already on sale

Oral-B’s iO line is its latest range of electric toothbrushes. iO brushes feature linear magnetic drive technology, using magnets for a quieter and more effective brushing performance. We rate it as ...
Seeking Alpha

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...